https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1368&p=28&f=G&l=50&d=PG01&S1=20210617.PD.&OS=PD/20210617&RS=PD/20210617
Allogene Reports Receives FDA Orphan Drug Designation For ALLO-715 For Treatment Of Multiple Myeloma
ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma Patients
Phase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic
